Policy Concerning Manufacturing

Takeda has established a global production system which ensures a stable supply of high quality products to global users. Since pharmaceutical products have a direct impact on people's life and health, Takeda will unrelentingly strive for quality control. High quality pharmaceutical products are manufactured in a production environment that meets the voluntary standards of Takeda GMP (Good Manufacturing Practices), which are even more stringent than legal GMP. Clearly demonstrating such, in sterilized rooms with strict clean controls, specially trained employees are engaged in an operation, wearing special sterile clothes. While Takeda promotes the outsourcing of manufacturing in efforts to develop a global production system, it works to accumulate technologies and information by restricting the sites that manufacture bulk compounds and require its proprietary high technologies to its own plants. Takeda Pharma Ireland Limited's (TPI) bulk pharmaceutical plant, which is the first such facility constructed outside of Japan, will commence operations within 2007. In addition, as for drug formulation, we manufacture pharmaceutical products at five global bases, including the Hikari and Osaka plants as well as our production plant in Italy, providing them to a global market. Together with the Hikari Plant of Japan (Yamaguchi pref.), we deliver bulk compounds from these two manufacturing bases to the world.